Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for B-Cell Acute Lymphoblastic Leukemia Clinical Trials
B-Cell Acute Lymphoblastic Leukemia clinical trials are recruiting across 56 cities. Here are the cities with the most active studies:
B-Cell Acute Lymphoblastic Leukemia Trial Phases
16 research organizations are sponsoring b-cell acute lymphoblastic leukemia trials.
About B-Cell Acute Lymphoblastic Leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is a fast-growing cancer of the B-type lymphocyte white blood cells. It is the most common childhood cancer but can also occur in adults. Treatment includes chemotherapy, targeted therapy, and CAR-T cell therapy.
Clinical trials are advancing new treatments for b-cell acute lymphoblastic leukemia. Currently, 25 studies are recruiting a combined 8,516 participants across the United States. Research is being conducted by 16 organizations including Children's Oncology Group, National Cancer Institute (NCI), Arkansas Children's Hospital Research Institute and 13 others.
2026 B-Cell Acute Lymphoblastic Leukemia Research Landscape
As of July 2026, the b-cell acute lymphoblastic leukemia clinical trial landscape includes 25 actively recruiting studies across 56 cities in the United States. These studies are collectively seeking 8,516 participants, with an average enrollment target of 341 per study.
The research spans multiple phases of development: 13 studies are in PHASE2, 9 studies are in PHASE1, 2 studies are in PHASE3, 1 study is in NA, 1 study is in EARLY_PHASE1. The presence of Phase 3 trials indicates that some b-cell acute lymphoblastic leukemia treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 16 different organizations, including Children's Oncology Group, National Cancer Institute (NCI), Arkansas Children's Hospital Research Institute, Etan Orgel, Imugene Limited, and 11 others. The large number of sponsors reflects significant research interest and investment in b-cell acute lymphoblastic leukemia treatment advancement.
Geographically, b-cell acute lymphoblastic leukemia trials are most concentrated in New York, New York (6 trials); Philadelphia, Pennsylvania (6 trials); Los Angeles, California (5 trials); Aurora, Colorado (5 trials); Birmingham, Alabama (4 trials) and 7 other cities.
Featured B-Cell Acute Lymphoblastic Leukemia Studies
Highlighted recruiting studies for b-cell acute lymphoblastic leukemia, selected by enrollment size and research scope.
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin ...
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine wheth...
Frequently Asked Questions About B-Cell Acute Lymphoblastic Leukemia Clinical Trials
Are there b-cell acute lymphoblastic leukemia clinical trials near me?
Yes, there are 25 b-cell acute lymphoblastic leukemia clinical trials currently recruiting across 56+ cities in the United States, including New York, New York; Philadelphia, Pennsylvania; Los Angeles, California. Browse the studies above to find one at a location convenient for you.
How do I join a b-cell acute lymphoblastic leukemia clinical trial?
To join a b-cell acute lymphoblastic leukemia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are b-cell acute lymphoblastic leukemia clinical trials free?
Yes, participation in b-cell acute lymphoblastic leukemia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of b-cell acute lymphoblastic leukemia treatments are being studied?
Current b-cell acute lymphoblastic leukemia clinical trials are testing a range of approaches across PHASE2 (13 studies), PHASE1 (9 studies), PHASE3 (2 studies), NA (1 study), EARLY_PHASE1 (1 study). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 16 research organizations.
Is it safe to participate in b-cell acute lymphoblastic leukemia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov